shares of immunic inc climbed in premarket trading thursday after the clinicalstage biopharmaceutical company said that the phase 2 emphasis trial for its imu838 multiple sclerosis drug is delivering positive results the company said the trial which assesses the efficacy of vidofludimus calcium in patients with relapsingremitting multiple sclerosis has shown encouraging signals in preventing 12week and 24week disabilityworsening events as compared to placebo imu838 is a small molecule investigational drug under development as an oral tablet formulation it said in premarket trading shares were up 12 at 159